Based on these assumptions, another study examined involvement of IFN-I cellular pathways in COVID-19 by analyzing the efficacy of recent pharmaceutical drugs such as Baricitinib, which exerts its activity by inhibiting JAK, in the JAK/STAT complex signaling pathway, which is upregulated in rheumatic conditions, with aberrant activation (46). The gene discussed is SOAT1; the disease is COVID-19.